molecules-logo

Journal Browser

Journal Browser

Special Issue "The Anticancer Drugs"

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: 30 June 2022.

Special Issue Editors

Prof. Dr. Anna Bajek
E-Mail Website
Guest Editor
Department of Tissue Engineering, The Ludwik Rydygier Collegium Medicum, Nicolaus Copernicus University, 87-100 Torun, Poland
Interests: anticancer therapy; personalized oncology; new drug development; microbiome; immunotherapy; cancer microenvironment; cancer cells culture; cancer stem cells
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Krzysztof Roszkowski
E-Mail Website
Guest Editor
Department of Oncology, Collegium Medicum, Nicolaus Copernicus University, Lukasiewicza str. 1, 85-821 Bydgoszcz, Poland
Interests: molecular markers of the effectiveness of oncological treatment; epigenetic factors affecting clinical decisions
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer is a serious problem that presents a huge threat to human health. During the last few years, there has been continued progress in anticancer drug development.

New agents ranging from small molecules to engineered antibodies and immune modulators have been approved for cancer treatment. Targeting drugs specifically to cancer cells can minimize the toxic effects on normal, healthy cells.

This Special Issue on “The Anticancer Drugs” aims to be an open forum where researchers may share their experiences and findings in this promising field. It is focused on the comprehensive and critical examination of current and emerging research on the design and development of advanced anticancer and their application to experimental and clinical therapeutics.

Contributions to this issue, in the form of both original research and review articles, may cover all aspects of new discovery and development of new therapeutic agents for cancer, using the newest techniques of biotechnology, pharmacology, and genetic engineering.

Prof. Dr. Anna Bajek
Prof. Dr. Krzysztof Roszkowski
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2300 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • anticancer therapy
  • drug development
  • personalized cancer treatment
  • nanotechnology
  • drug resistance in cancer
  • drug design
  • resistance
  • targeted therapy

Published Papers

This special issue is now open for submission.
Back to TopTop